Results of a trial looking at the use of ropinirole hydrochloride for amyotrophic lateral sclerosis have been published in Cell … read more

A study published in the Journal of Neurology, Neurosurgery and Psychiatry looks at neurodegenerative disease risk among former international rugby … read more

New results from the FIELD (Football’s InfluencE on Lifelong health and Dementia risk) study were published on the evening of … read more

Around 5,000 people in the UK have motor neurone disease (MND) – also known as amyotrophic lateral sclerosis (ALS). Two … read more

Results of a phase 3 clinical trial looking at the use of tofersen for motor neurone disease (MND) has been … read more

A study published in EBioMedicine looks at physical exercise and development of the neurodegenerative condition motor neurone disease (MND).   … read more

Researchers publishing in The Journal of Neurology Neurosurgery & Psychiatry investigate the association between physical activity (PA) and amyotrophic lateral sclerosis (ALS) in population-based case-control studies in three European countries using a validated and harmonised questionnaire read more

Researchers publishing in Occupational and Environmental Medicine report that repeated exposure to low-frequency electromagnetic fields could increase risk of amyotrophic lateral sclerosis (ALS). read more

Amyotrophic lateral sclerosis (ALS) is a form of motor neuron disease and is the subject of a paper in JAMA Neurology which reports that environmental pollutants measured in the blood were associated with the disease. read more

Research suggested a link between ring finger length (determined by testosterone exposure in the womb) and the incidence of motor neurone disease. read more

The Motor Neurone Disease Association has announced its biggest ever funding for its first stem cell programme which will enable scientists to perform detailed studies on human motor neurons containing known causes of motor neuron disease (MND). Four leading scientists involved came to the SMC to tell journalists about the programme and its aims. read more

The paper reports on a trial in the US which has failed to replicate the initial success of lithium as a treatment for motor neurone disease. read more

Researchers at the Institute of Psychiatry at Kings College London have discovered the second gene involved with motor neurone disease in as many years. read more

Motor Neurone Disease (MND) is a rapidly progressive, fatal disease that can affect any adult at any time. There are around 5000 people living with MND in the UK at any one time; and half of those affected will die within 14 months of diagnosis. The cause of over 95% of cases is still unknown, and there is currently no cure or effective treatment. In a significant first step, the MND Association have launched clinical trials with lithium, which could provide a promising new treatment avenue. read more

Research published in Science has provided new clues as to the cause of motor neurone disease; researchers at King’s College London have found mutations in a gene that causes the disease, allowing scientists to understand the mechanisms that initiate disease, which they hope will help identify new therapeutic targets. read more

Our first ever regional briefing bringing Ian Wilmut and colleagues to announce to the press in Edinburgh the result of their application to the HFEA to conduct therapeutic cloning in their research of Motor Neurone Disease. read more

Scientists and patients comment on the decision by the HFEA to grant a human therapeutic cloning license to Ian Wilmut and colleagues. read more

Ian Wilmut and his colleagues brief the press as he applies for a license to use cloned human embryos to study motor neurone disease. read more

As Ian Wilmut submits his application for a license to perform therapeutic cloning to the HFEA, scientists respond. read more